We enable physicians to extend disease management into the patient’s home to obtain optimal vision outcomes
The Heart, Soul and Mind of Notal Vision begins with the Eyes
Notal Vision’s executive team is composed of highly and diversely experienced individuals united by their focus on the patient and a passion for pioneering value-added paradigm shifts in eye care. Together they represent more than 150 years of ophthalmology and industry expertise spanning product development, clinical development, and commercialization.
The Independent Diagnostic Testing Facility (IDTF) of Notal Vision is a medical provider, directed by licensed ophthalmologists. The IDTF is responsible for the collection, analyses, and reporting of all ForeseeHome patient testing results to both prescribing physicians and patients. Notal Vision IDTF physicians provide timely medical reports to doctors when a significant change in a patient’s testing results takes place, facilitating earlier detection and superior vision outcomes. The patient and physician enjoy 24/7 online access to testing results and compliance. Both doctors and patients are supported by a team of certified ophthalmic technicians and prescription specialists that manage the day-to-day operations of the IDTF and form the point of contact for testing related inquiries and feedback.
Dr Sanborn is a board-certified ophthalmologist. Following residency, he completed a fellowship in neuro-ophthalmology at the Wilmer institute, Johns Hopkins Hospital, Baltimore followed by a retina fellowship at the Wills Eye Hospital in Philadelphia. Dr. Sanborn was a Fulbright Scholar at the St. John Ophthalmic Hospital in the West Bank and a World Health Organization Fellow in the People’s Republic of China. Serving as a full-time faculty member at several institutions including the University of Texas Southwestern at Dallas, he has authored and/or co-authored several textbooks as well as numerous journal publications. With a history of active participation in clinical research, Dr. Sanborn was a principal investigator or co-investigator in Lucentis® and Eylea® age-related macular degeneration and diabetic macular edema trials, as well as the National Eye Institute’s SCORE1 studies for retinal vein occlusions. Dr. Sanborn joined the Notal Vision Data Monitoring Facility in 2015 as the Clinical Director, bringing his expertise and passion for improving patient outcomes to the pioneering field of patient-activated, cloud-based disease detection and monitoring in ophthalmology.
1Standard Care vs Corticosteroid for Retinal Vein Occlusion
Dr. Jacobs is a board certified ophthalmologist. Following residency, Dr. Jacobs served as a clinical instructor at the University of Maryland where she also completed a fellowship in Cornea, External Disease and Refractive Surgery in the Department of Ophthalmology, University of Maryland at Baltimore. Dr. Jacobs has nearly 20 years of ophthalmic experience in private practice providing comprehensive ophthalmic care as well as performing general ophthalmic and corneal surgery in Virginia and Maryland. Dr Jacobs is well respected among her peers who have selected her in 2015 as one of Northern Virginia’s top doctors. Dr. Jacobs is a fellow of the American Academy of Ophthalmology, and is a member of The Northern Virginia Academy of Ophthalmology, The Cornea Society, and the American Society of Cataract and Refractive Surgery. Dr. Jacobs is highly rated by her patients and takes pride in keeping abreast of the latest technological advances to provide her patients with the best care. Dr. Jacobs joined the Notal Vision Data Monitoring Facility in 2017 as one of our Medical Directors bringing her expertise and passion for patient education, early intervention and state-of-the-art ophthalmic care to the pioneering field of patient-activated cloud-based disease detection and monitoring in ophthalmology.
Below is a list of the performance standards that an IDTF must meet in order to obtain or maintain their Medicare billing privileges. These standards, in their entirety, can be found in 42 Code of Federal Regulations (C.F.R) section 410.33(g).
1. Operate its business in compliance with all applicable Federal and State licensure and regulatory requirements for the health and safety of patients.
2. Provides complete and accurate information on its enrollment application. Changes in ownership, changes of location, changes in general supervision, and adverse legal actions must be reported to the Medicare fee-for-service contractor on the Medicare enrollment application within 30 calendar days of the change. All other changes to the enrollment application must be reported within 90 calendar days.
3. Maintain a physical facility on an appropriate site. For the purposes of this standard, a post office box, commercial mail box, hotel or motel is not considered an appropriate site.
(i) The physical facility, including mobile units, must contain space for equipment appropriate to the services designated on the enrollment application, facilities for hand washing, adequate patient privacy accommodations, and the storage of both business records and current medical records within the office setting of the IDTF, or IDTF home office, not within the actual mobile unit.
(ii) IDTF suppliers that provide services remotely and do not see beneficiaries at their practice location are exempt from providing hand washing and adequate patient privacy accommodations.
4. Have all applicable diagnostic testing equipment available at the physical site excluding portable diagnostic testing equipment. A catalog of portable diagnostic equipment, including diagnostic testing equipment serial numbers, must be maintained at the physical site. In addition, portable diagnostic testing equipment must be available for inspection within two business days of a CMS inspection request. The IDTF must maintain a current inventory of the diagnostic testing equipment, including serial and registration numbers, provide this information to the designated fee-for-service contractor upon request, and notify the contractor of any changes in equipment within 90 days.
5. Maintain a primary business phone under the name of the designated business. The primary business phone must be located at the designated site of the business, or within the home office of the mobile IDTF units. The telephone number or toll-free numbers must be available in a local directory and through directory assistance.
6. Have a comprehensive liability insurance policy of at least $300,000 per location that covers both the place of business and all customers and employees of the IDTF. The policy must be carried by a non-relative-owned company. Failure to maintain required insurance at all times will result in revocation of the IDTF’s billing privileges retroactive to the date the insurance lapsed. IDTF suppliers are responsible for providing the contact information for the issuing insurance agent and the underwriter. In addition, the IDTF must:
(i) Ensure that the insurance policy must remain in force at all times and provide coverage of at least $300,000 per incident; and
(ii) Notify the CMS-designated contractor in writing of any policy changes or cancellations.
7. Agree not to directly solicit patients, which include, but is not limited to, a prohibition on telephone, computer, or in-person contacts. The IDTF must accept only those patients referred for diagnostic testing by an attending physician, who is furnishing a consultation or treating a beneficiary for a specific medical problem and who uses the results in the management of the beneficiary’s specific medical problem. Non-physician practitioners may order tests as set forth in §410.32(a)(3).
8. Answer, document, and maintain documentation of a beneficiary’s written clinical complaint at the physical site of the IDTF (for mobile IDTFs, this documentation would be stored at their home office.) This includes, but is not limited to, the following:
(i) The name, address, telephone number, and health insurance claim number of the beneficiary.
(ii) The date the complaint was received; the name of the person receiving the complaint; and a summary of actions taken to resolve the complaint.
(iii) If an investigation was not conducted, the name of the person making the decision and the reason for the decision.
9. Openly post these standards for review by patients and the public.
10. Disclose to the government any person having ownership, financial, or control interest or any other legal interest in the supplier at the time of enrollment or within 30 days of a change.
11. Have its testing equipment calibrated and maintained per equipment instructions and in compliance with applicable manufacturers suggested maintenance and calibration standards.
12. Have technical staff on duty with the appropriate credentials to perform tests. The IDTF must be able to produce the applicable Federal or State licenses or certifications of the individuals performing these services.
13. Have proper medical record storage and be able to retrieve medical records upon request from CMS or its fee-for-service contractor within 2 business days.
14. Permit CMS, including its agents, or its designated fee-for-service contractors, to conduct unannounced, on-site inspections to confirm the IDTF’s compliance with these standards. The IDTF must be accessible during regular business hours to CMS and beneficiaries and must maintain a visible sign posting the normal business hours of the IDTF.
15. With the exception of hospital-based and mobile IDTFs, a fixed-base IDTF does not include the following:
(i) Sharing a practice location with another Medicare-enrolled individual or organization.
(ii) Leasing or subleasing its operations or its practice location to another Medicare-enrolled individual or organization.
(iii) Sharing diagnostic testing equipment using in the initial diagnostic test with another Medicare-enrolled individual or organization.
16. Enrolls in Medicare for any diagnostic testing services that it furnishes to a Medicare beneficiary, regardless of whether the service is furnished in a mobile or fixed-base location.
17. Bills for all mobile diagnostic services that are furnished to a Medicare beneficiary, unless the mobile diagnostic service is part of a service provided under arrangement as described in section 1861(w)(1) of the Act.